Precision BioSciences Inc. Form 8-K Summary
Business Context and Reporting Period
Precision BioSciences, Inc. (DTIL) filed this Current Report on Form 8-K on May 21, 2026, regarding events occurring at its annual meeting of stockholders held on the same date. The company is incorporated in Delaware and trades on the Nasdaq Capital Market.
Key Financial Metrics
This filing is a current report regarding corporate governance and shareholder voting results. It does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.
Material Changes and Corporate Actions
- Equity Plan Amendment: Stockholders approved an amendment to the 2019 Incentive Award Plan, increasing the number of shares available for issuance by 3,800,000.
- Charter Amendment: Stockholders approved an amendment to the Certificate of Incorporation to provide for the exculpation of certain officers as permitted by Delaware law. This amendment was filed with the Delaware Secretary of State on May 22, 2026.
- Director Elections: Melinda Brown and Geno Germano were elected as Class I directors to serve until the 2029 annual meeting.
- Accounting Firm Ratification: Deloitte & Touche LLP was ratified as the independent registered public accounting firm for the year ending December 31, 2026.
Voting Results and Management Commentary
Approximately 86% of outstanding common stock was represented at the meeting. Key voting outcomes included:
- Executive Compensation (Say-on-Pay): Approved with 18,696,193 votes FOR and 612,836 votes AGAINST.
- Equity Plan Amendment (Item 4): Approved with 11,170,635 votes FOR and 8,145,992 votes AGAINST. This proposal received a significant number of votes against compared to other items.
- Charter Amendment (Item 5): Approved with 17,909,703 votes FOR and 1,411,694 votes AGAINST.
- Adjournment Authority (Item 6): Approved with 16,653,283 votes FOR and 5,647,737 votes AGAINST.
The filing does not contain specific management commentary, forward-looking guidance, risk factors, or contingencies beyond the standard incorporation by reference to the Proxy Statement.
Investor Verification Checklist
- Review the full text of the Amended 2019 Incentive Award Plan (Exhibit 10.1) to understand the terms of the 3.8 million share increase.
- Analyze the Proxy Statement filed on April 8, 2026, for detailed rationale behind the equity plan amendment and the significant "Against" votes received.
- Verify the effective date of the Certificate of Incorporation amendment (May 22, 2026) and its specific impact on officer liability under Delaware law.
- Confirm the tenure of newly elected directors Melinda Brown and Geno Germano through the 2029 annual meeting.